inflammation

Biotech

Roivant CEO: New data could make '23 'single most exciting year'

Roivant CEO Matt Gline is bullish on the company's 2023 prospects a week after reporting a phase 2 win of its ulcerative colitis med.
Max Bayer Jan 10, 2023 9:58am

Washing out WASH protein complex drives inflammation in mice

Sep 26, 2022 10:10am

Novartis' MS drug Gilenya could inspire new CKD treatment

Aug 18, 2022 4:55pm

Lipids that wind down inflammation may be a new tool against MS

Apr 28, 2022 7:20am

Penn scientists discover new cell type in the lung

Apr 5, 2022 8:30am

Sanofi pulls IGM into dealmaking whirlwind, paying $150M upfront

Mar 29, 2022 7:20am